Form 4: Alector Director Paula Hammond Receives Significant Equity Compensation Awards

Alector, Inc. Director Paula Hammond was granted 28,700 restricted stock units and options to purchase 9,450 shares of common stock on June 11, 2025, as part of her compensation.

Summary

• Paula Hammond, a Director of Alector, Inc., received new equity awards on June 11, 2025.
• She was granted 28,700 Restricted Stock Units (RSUs) at a price of $0.00, which are set to vest on the earlier of June 11, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Following this RSU grant, Ms. Hammond's direct beneficial ownership of common stock increased to 88,909 shares.
• Additionally, Ms. Hammond was granted options to purchase 9,450 shares of common stock at an exercise price of $1.63 per share.
• These stock options will vest in 12 equal monthly installments beginning on July 11, 2025, or fully vest on the earlier of the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders, and are set to expire on June 10, 2035.
• After this transaction, Ms. Hammond directly beneficially owns 9,450 stock options.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a positive sign of aligning interests and retaining talent. While not a major catalyst, it reflects standard corporate governance and compensation practices, contributing to a neutral to slightly positive sentiment.

Positives

• The grant of 28,700 Restricted Stock Units (RSUs) to a director aligns management's long-term interests with shareholder value.
• The issuance of options to purchase 9,450 shares at an exercise price of $1.63 provides a performance-based incentive for the director.
• The structured vesting schedules for both RSUs and stock options are designed to encourage continued service and commitment to the company's success.

Risks

• The value of the granted Restricted Stock Units is directly tied to the future market performance of Alector, Inc.'s common stock, exposing the holder to market price fluctuations.
• The stock options' value is contingent on the stock price exceeding the $1.63 exercise price; if the stock price remains below this, the options may not be profitable to exercise.

Future Outlook

The document primarily reports a past equity compensation transaction and does not provide a general future outlook for the company. However, the vesting schedules for the granted equity awards indicate future equity ownership for the director, aligning her incentives with the company's long-term performance.

Industry Context

This Form 4 filing details a standard equity compensation grant to a director, a common practice across various industries, particularly in the biotechnology and pharmaceutical sectors. Such grants are integral to corporate governance, serving to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• The grant of both Restricted Stock Units (RSUs) and stock options to a director is a widely adopted compensation strategy in the biotechnology and pharmaceutical industries, consistent with practices observed in companies like Biogen Inc. or Gilead Sciences, Inc., which use similar equity-based incentives to align executive and board interests with long-term company growth.
• The vesting schedules, including a one-year cliff or monthly installments, are typical for equity compensation plans designed to ensure retention and sustained commitment from key personnel, mirroring structures seen in compensation packages at comparable life sciences firms.
• The exercise price of $1.63 for the options is presumed to be the market price on the grant date, which is standard for incentive stock options and aligns with common industry practices for fair market value grants.

Corporate Governance

Related Party Transactions

• The equity compensation grant to Paula Hammond, a Director of Alector, Inc., constitutes a related party transaction, which is a standard practice for executive and board remuneration.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance. However, these awards will result in minor dilution upon vesting and exercise.
• Employees: While not directly impacting general employees, this compensation reflects the company's overall philosophy regarding incentivizing its leadership.

Next Steps

• Vesting of 28,700 Restricted Stock Units on the earlier of June 11, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Monthly vesting of 9,450 stock options beginning July 11, 2025, or full vesting on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders.
• Potential exercise of stock options by their expiration date of June 10, 2035.

Key Dates

Recommendation

Keywords

SEC Form 4, Alector Inc., ALEC, Paula Hammond, Director, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Beneficial Ownership